Treatment and Outcome of AIDS-related Lymphoma

艾滋病相关淋巴瘤的治疗和结果

• 批准号: 6923728
• 负责人: CATHERINE A DIAMOND
• 金额: $ 12.72万
• 依托单位: UNIVERSITY OF CALIFORNIA-IRVINE
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-08-01 至 2007-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6923728
• 关键词: AIDS; cancer registry /resource; clinical research; combination chemotherapy; comorbidity; disease /disorder proneness /risk; health care service availability; helper T lymphocyte; human data; human subject; interview; long term survivor; longitudinal human study; neoplasm /cancer epidemiology; neoplasm /cancer therapy; nonHodgkin' s lymphoma; prognosis; quality of life; racial /ethnic difference; virus load

Non-Hodgkin's lymphoma (NHL) is an increasing cause of death among people with acquired immunodeficiency (AIDS) due to declining rates of opportunistic infection (OI) with the use of highly active antiretroviral therapy (HAART). While the prognosis of AIDS- related NHL has been poor in the past, HAART may improve outcomes. Specific Aims: 1) We will identify NHL patients with and without AIDS from the population-based cancer registry using a rapid case ascertainment method. 2) We will describe HIV-specific patient and treatment characteristics of AIDS-NHL patients and distinguish which factors influence prognosis. 3) We will describe tumor characteristics and cancer treatment in NHL patients with and without AIDS and distinguish which oncologic features influence prognosis. 4) We will determine how the use of HAART influences the International Prognostic Index (IPI) and form an original prognostic model. Research Design: Using rapid case ascertainment, we will contact all AIDS-NHL cases reported in a two-year period to the cancer registry for Orange, San Diego, and Imperial Counties and a sample of non- AIDS NHL cases matched on age, sex and race/ethnicity reported during the same two-year period. We will perform interviews and chart reviews on NHL patients to collect information on biologic factors that influence prognosis such as such as NHL site, stage, and pathologic grade as well as patient-specific features such as race/ethnicity, performance status, and health care access. We will gather data on HIV-specific features including CD4 cell count, HIV viral load, HIV risk factors, and use of HAART for NHL patients with AIDS. We will compare survival, development of co-morbidities/OI, and quality of life (QOL) between NHL patients with and without AIDS over a three-year follow-up period between AIDS patients who receive HAART and those who do not. Lastly, we will determine how the use of HAART influences the IPI and develop a prognostic model that incorporates HIV-related factors, tumor characteristics, HAART, and chemotherapy.

由于使用高效抗逆转录病毒疗法 (HAART) 降低了机会性感染 (OI) 率，非霍奇金淋巴瘤 (NHL) 成为获得性免疫缺陷 (AIDS) 患者日益增加的死亡原因。 虽然过去 AIDS 相关 NHL 的预后很差，但 HAART 可能会改善预后。具体目标： 1) 我们将使用快速病例确定方法，从基于人群的癌症登记处识别患有或不患有艾滋病的 NHL 患者。 2）我们将描述HIV特异性患者和AIDS-NHL患者的治疗特征，并区分哪些因素影响预后。 3) 我们将描述患有和不患有艾滋病的 NHL 患者的肿瘤特征和癌症治疗，并区分哪些肿瘤学特征影响预后。 4）我们将确定HAART的使用如何影响国际预后指数（IPI）并形成原始的预后模型。研究设计：通过快速病例确定，我们将联系奥兰治县、圣地亚哥县和帝国县癌症登记处两年内报告的所有 AIDS-NHL 病例，以及年龄、性别相匹配的非 AIDS NHL 病例样本以及同一两年期间报告的种族/民族。 我们将对 NHL 患者进行访谈和图表审查，以收集影响预后的生物学因素的信息，例如 NHL 部位、分期和病理分级以及患者特定特征，例如种族/民族、体能状态和医疗保健使用权。 我们将收集有关 HIV 特异性特征的数据，包括 CD4 细胞计数、HIV 病毒载量、HIV 危险因素以及患有 AIDS 的 NHL 患者使用 HAART 的情况。 我们将比较接受 HAART 的 AIDS 患者与未接受 HAART 的 AIDS 患者在三年随访期内，患有和未患有 AIDS 的 NHL 患者的生存率、合并症/OI 的发展以及生活质量 (QOL)。 最后，我们将确定HAART的使用如何影响IPI，并开发一个包含HIV相关因素、肿瘤特征、HAART和化疗的预后模型。